Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Covington
Moodys
Chubb
Fish and Richardson
Cipla
US Army
Medtronic
Teva

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018132

« Back to Dashboard

NDA 018132 describes DOPAMINE HYDROCHLORIDE, which is a drug marketed by Abbott, Abraxis Pharm, Baxter Hlthcare, Hikma Intl Pharms, Hospira, Igi Labs Inc, Intl Medication, Luitpold, Lyphomed, Smith And Nephew, Teligent, Teva Parenteral, Warner Chilcott, and B Braun, and is included in thirty-six NDAs. It is available from six suppliers. Additional details are available on the DOPAMINE HYDROCHLORIDE profile page.

The generic ingredient in DOPAMINE HYDROCHLORIDE is dopamine hydrochloride. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the dopamine hydrochloride profile page.
Summary for 018132
Tradename:DOPAMINE HYDROCHLORIDE
Applicant:Hospira
Ingredient:dopamine hydrochloride
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 018132
Ingredient-typeCatecholamines
Medical Subject Heading (MeSH) Categories for 018132
Suppliers and Packaging for NDA: 018132
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DOPAMINE HYDROCHLORIDE dopamine hydrochloride INJECTABLE;INJECTION 018132 NDA Hospira, Inc. 0409-5820 N 0409-5820-01
DOPAMINE HYDROCHLORIDE dopamine hydrochloride INJECTABLE;INJECTION 018132 NDA Hospira, Inc. 0409-9104 N 0409-9104-20

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength40MG/ML
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength80MG/100ML
Approval Date:Feb 4, 1982TE:APRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength160MG/100ML
Approval Date:Feb 4, 1982TE:APRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Express Scripts
AstraZeneca
US Department of Justice
UBS
Medtronic
Merck
Cantor Fitzgerald
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.